{"product_id":"thermal-ablation-for-papillary-thyroid-microcarcinoma-what-patients-should-know-about-this-promising-treatment","title":"Thermal Ablation for Papillary Thyroid Microcarcinoma: What Patients Should Know About This Promising Treatment","description":"\u003cp\u003eThermal ablation (TA) is a family of heat-based treatments that destroy tumors without surgery. TA is emerging as a safe and effective alternative to thyroid surgery for papillary thyroid microcarcinoma (PTMC). PTMC is a thyroid cancer 10 mm or smaller. A review of dozens of clinical studies found that microwave ablation (MWA), laser ablation (LA), and radiofrequency ablation (RFA) shrank tumors by 96% to nearly 100% on average. Follow-up ranged from 6 to 64.2 months. Compared with standard surgery (total thyroidectomy or lobectomy), thermal ablation produced far fewer complications. Thermal ablation showed no statistically significant difference in cancer recurrence. Thermal ablation also had significantly shorter operating times, less blood loss, shorter hospital stays, and lower costs. The authors caution, however, that most evidence comes from retrospective studies in Asian populations and that large, multicenter, randomized controlled trials (RCTs) are still urgently needed.\u003c\/p\u003e\n\n\u003ch1\u003eMethods description Thermal Ablation for Papillary Thyroid Microcarcinoma- How Far We Have Come\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why Small Thyroid Cancers Matter\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#what-is-ta\"\u003eWhat Is Thermal Ablation?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#mwa\"\u003eMicrowave Ablation (MWA)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#la\"\u003eLaser Ablation (LA)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rfa\"\u003eRadiofrequency Ablation (RFA)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#vs-surgery\"\u003eHow Thermal Ablation Compares With Surgery\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#complications\"\u003eComplications and Side Effects\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow This Review Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Evidence\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eThermal ablation uses heat to destroy papillary thyroid microcarcinoma (10 mm or smaller) without surgery, guided by ultrasound.\u003c\/li\u003e\n\u003cli\u003eIn reviewed studies, microwave, laser, and radiofrequency ablation shrank tumors by 96% to nearly 100% on average.\u003c\/li\u003e\n\u003cli\u003eCompared with surgery, thermal ablation had fewer complications, shorter hospital stays, less blood loss, and lower costs.\u003c\/li\u003e\n\u003cli\u003eRecurrence appeared similar to surgery in the largest comparison: 4.2% with microwave ablation versus 4.2% with surgery.\u003c\/li\u003e\n\u003cli\u003eMost evidence comes from retrospective studies in Asian populations; large randomized trials are still needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why Small Thyroid Cancers Matter\u003c\/h2\u003e\n\n\u003cp\u003eThyroid cancer diagnoses have climbed sharply around the world in recent decades. A major driver is not that more people are truly developing aggressive cancer. A major driver is that imaging tests and routine physical exams are finding very small tumors. These very small tumors would never have caused symptoms. Researchers call this \u003cstrong\u003eoverdetection\u003c\/strong\u003e — finding disease that would otherwise have gone unnoticed and possibly never caused harm.\u003c\/p\u003e\n\n\u003cp\u003eThe most common thyroid cancer type is \u003cstrong\u003edifferentiated thyroid carcinoma (DTC)\u003c\/strong\u003e, a group of cancers arising from thyroid cells that still resemble normal thyroid tissue. Within that group, \u003cstrong\u003epapillary thyroid carcinoma (PTC)\u003c\/strong\u003e is the most frequent. When a papillary tumor measures 10 mm or less across (about 0.4 inches), it is called \u003cstrong\u003epapillary thyroid microcarcinoma (PTMC)\u003c\/strong\u003e. PTMC makes up a substantial share of all DTC cases.\u003c\/p\u003e\n\n\u003cp\u003eToday in China, the standard treatment for PTMC is \u003cstrong\u003ethyroid lobectomy\u003c\/strong\u003e (removing half the thyroid gland) plus \u003cstrong\u003eselective central lymph node dissection (SCLND)\u003c\/strong\u003e, a procedure that removes nearby lymph nodes in the center of the neck to check for spread. Yet the review authors point out an uncomfortable fact: many of these tiny tumors never grow, or grow extremely slowly, over years of follow-up.\u003c\/p\u003e\n\n\u003cp\u003eSurgery itself has improved. Techniques have advanced from traditional open thyroidectomy to \u003cstrong\u003eendoscopic thyroidectomy\u003c\/strong\u003e, in which instruments and a camera are inserted through small incisions. Even so, recent literature still reports surgical complications. This has fueled growing concern about both overdetection and overtreatment of PTMC, and it has driven researchers to look for alternatives.\u003c\/p\u003e\n\n\u003cp\u003eTwo main alternatives have emerged:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eActive surveillance (AS)\u003c\/strong\u003e — carefully monitoring the tumor with repeat ultrasound instead of treating it immediately.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThermal ablation (TA)\u003c\/strong\u003e — using heat to destroy the tumor in place.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSome patients find active surveillance difficult to accept. The review notes that a portion of people diagnosed with PTMC experience anxiety and distress about simply \"carrying\" a tumor. Many of these patients prefer an active intervention over watchful waiting. Thermal ablation has therefore been introduced into clinical practice as an option for patients with low-risk PTMC.\u003c\/p\u003e\n\n\u003ch2 id=\"what-is-ta\"\u003eWhat Is Thermal Ablation?\u003c\/h2\u003e\n\n\u003cp\u003eThermal ablation refers to techniques that use extreme heat to kill tumor cells. The heat causes \u003cstrong\u003ecoagulation necrosis\u003c\/strong\u003e — a process in which proteins in the cells break down and the tissue dies. The dead tissue is then gradually reabsorbed by the body.\u003c\/p\u003e\n\n\u003cp\u003eThree main technologies are used for PTMC, and each generates heat differently:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMicrowave ablation (MWA)\u003c\/strong\u003e — high-frequency electromagnetic waves create a broad thermal effect that kills tumor cells quickly through protein denaturation (protein breakdown caused by heat).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLaser ablation (LA)\u003c\/strong\u003e — a thin fiber connected to a continuous-wave \u003cstrong\u003eneodymium yttrium-aluminum-garnet (Nd:YAG)\u003c\/strong\u003e laser source operates at a wavelength of 1064 nm. It heats tissue around the fiber tip under ultrasound guidance.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRadiofrequency ablation (RFA)\u003c\/strong\u003e — rapidly alternating radiofrequency electrical current creates frictional heat around probes placed inside the tissue, producing cell death by coagulation necrosis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eBecause all three approaches are guided by ultrasound, doctors can direct the heat precisely at the tumor. The early studies of these techniques in thyroid disease focused on \u003cstrong\u003ebenign thyroid nodules\u003c\/strong\u003e and \u003cstrong\u003eparathyroid adenoma\u003c\/strong\u003e (a non-cancerous parathyroid gland tumor). Success there led researchers to test the same tools on low-risk PTMC, defined as clinical stage \u003cstrong\u003eT1N0M0\u003c\/strong\u003e — a tumor confined to the thyroid (T1), with no lymph node spread (N0) and no distant spread (M0).\u003c\/p\u003e\n\n\u003cp\u003eEarly results showed meaningful benefits: significant shrinkage of the primary tumor, satisfactory tumor resolution, and fewer postoperative complications compared with routine surgery. The review set out to summarize these results and to compare the numbers directly across techniques.\u003c\/p\u003e\n\n\u003ch2 id=\"mwa\"\u003eMicrowave Ablation (MWA)\u003c\/h2\u003e\n\n\u003cp\u003eMicrowave ablation was widely used first for benign lesions, then expanded to solid small malignant tumors of the liver, kidney, and lung. Studies consistently showed shorter operating time, shorter recovery, shorter hospital stays, and strong therapeutic results.\u003c\/p\u003e\n\n\u003cp\u003eThe first prospective study of MWA in PTMC enrolled a small, carefully selected group of 21 patients with T1N0M0 disease. Their average tumor volume dropped dramatically — from \u003cstrong\u003e89.5 ± 20.1 mm³ to 8.7 ± 9.3 mm³\u003c\/strong\u003e. But there was a catch: the complete tumor disappearance rate was only \u003cstrong\u003e19%\u003c\/strong\u003e. That low number worried patients about how well the treatment was working. In fact, three patients in that study chose to undergo subtotal thyroidectomy and central node dissection within two months after their ablation.\u003c\/p\u003e\n\n\u003cp\u003eEven so, the same study found few complications, no recurrence, and no metastasis after MWA. That early result opened the door to further research. As follow-up lengthened and study populations grew, the safety and effectiveness picture became clearer.\u003c\/p\u003e\n\n\u003cp\u003eKey findings from the larger MWA studies include:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe longest prospective follow-up reached \u003cstrong\u003e101 months\u003c\/strong\u003e, with an average follow-up of \u003cstrong\u003e37.2 months\u003c\/strong\u003e. In that series of \u003cstrong\u003e119 patients\u003c\/strong\u003e, the volume reduction rate (VRR — the percentage by which tumor volume shrank) reached \u003cstrong\u003e99.40%\u003c\/strong\u003e, complete absorption was \u003cstrong\u003e78.1%\u003c\/strong\u003e, complications occurred in \u003cstrong\u003e10.9% (13 patients)\u003c\/strong\u003e, and recurrence in \u003cstrong\u003e0.88% (1 patient)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eAnother 41-patient series had an average follow-up of \u003cstrong\u003e60 months\u003c\/strong\u003e — the longest reported in the literature at the time. The VRR reached \u003cstrong\u003e99.37%\u003c\/strong\u003e, complete absorption \u003cstrong\u003e97.6%\u003c\/strong\u003e, complications \u003cstrong\u003e4.8% (2 patients)\u003c\/strong\u003e, and recurrence \u003cstrong\u003e0\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eA retrospective study of \u003cstrong\u003e185 patients\u003c\/strong\u003e with a mean follow-up of 20.7 months reported a VRR of \u003cstrong\u003e98.65%\u003c\/strong\u003e, complete absorption of \u003cstrong\u003e84.5%\u003c\/strong\u003e, complications in \u003cstrong\u003e8.6% (16 patients)\u003c\/strong\u003e, and no recurrences.\u003c\/li\u003e\n  \u003cli\u003eA retrospective study of \u003cstrong\u003e33 patients\u003c\/strong\u003e followed for a mean of 23.3 months reported the highest VRR of all — \u003cstrong\u003e99.80%\u003c\/strong\u003e — with complete absorption of \u003cstrong\u003e97.0%\u003c\/strong\u003e, complications in \u003cstrong\u003e9.10% (3 patients)\u003c\/strong\u003e, and no recurrences.\u003c\/li\u003e\n  \u003cli\u003eA study of \u003cstrong\u003e168 patients\u003c\/strong\u003e followed for a mean of 25.1 months reported complete absorption of \u003cstrong\u003e22.7%\u003c\/strong\u003e, complications in \u003cstrong\u003e4.2% (7 patients)\u003c\/strong\u003e, and recurrence in \u003cstrong\u003e4.20% (7 patients)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eA 46-patient study with a mean 42-month follow-up reported a VRR of \u003cstrong\u003e81.33%\u003c\/strong\u003e, complete absorption of \u003cstrong\u003e15.2%\u003c\/strong\u003e, complications in \u003cstrong\u003e4.3% (2 patients)\u003c\/strong\u003e, and no recurrences.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe most common complications tied to MWA were \u003cstrong\u003eburning sensation, hoarseness, and hemorrhage\u003c\/strong\u003e (bleeding). Across trials, microwave power output ranged from \u003cstrong\u003e20 W to 40 W\u003c\/strong\u003e. Higher power and longer procedure times raised the risk of transient thermal damage to surrounding tissue.\u003c\/p\u003e\n\n\u003cp\u003eTo make sure the tumor is fully destroyed and to prevent regrowth at the edges, doctors typically ablate \u003cstrong\u003e5 mm beyond the visible lesion\u003c\/strong\u003e. That extra margin helps, but it can also affect nearby nerves and blood vessels — which explains some of the hoarseness and burning complaints.\u003c\/p\u003e\n\n\u003cp\u003eThe review authors note that most patients in these studies came from Asia, especially China, and most studies were retrospective or prospective observational designs. That means there is still a shortage of high-level evidence from large, multi-ethnic randomized controlled trials (RCTs) — studies in which patients are randomly assigned to different treatments.\u003c\/p\u003e\n\n\u003ch2 id=\"la\"\u003eLaser Ablation (LA)\u003c\/h2\u003e\n\n\u003cp\u003eLaser ablation works through a thin optical fiber that delivers laser energy directly into the tumor. Because the energy is focused, LA has a lower chance of damaging surrounding tissue than some other methods. It has been used to treat early-stage cancers including small hepatocellular carcinoma (liver cancer), small renal cell carcinoma (kidney cancer), and even low-risk basal cell carcinoma (a common skin cancer).\u003c\/p\u003e\n\n\u003cp\u003eAbout a decade before this review, researchers led by Papini introduced LA for a solitary PTMC and reported satisfactory results. Since then, many studies — especially from China — have reached similar conclusions about its feasibility and safety.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eTemperature control is the critical variable.\u003c\/strong\u003e Two failure modes exist:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eIf the temperature around the fiber tip stays consistently high — especially \u003cstrong\u003eabove 110 °C\u003c\/strong\u003e — tissue can become carbonized (charred). That delays wound healing in the short term.\u003c\/li\u003e\n  \u003cli\u003eIf the temperature does not rise high enough, the moderate heating may fail to destroy all tumor cells, leaving residual tumor tissue that can grow back. This risk was demonstrated in laboratory experiments on liver cancer cells, operating through the \u003cstrong\u003ePI3K\/mTOR\/AKT signaling pathway\u003c\/strong\u003e (a chain of molecular signals that controls cell growth and survival).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe largest comparison to date pitted LA directly against MWA in PTMC patients. Most between-group differences were not statistically significant, but two stood out:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eMWA achieved a higher volume reduction rate than LA: \u003cstrong\u003e99.8% vs 96.8%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eLA had a lower complication rate than MWA: \u003cstrong\u003e2.9% vs 9.1%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe explanation is straightforward. The output power of the LA device in that study was only \u003cstrong\u003e3 W\u003c\/strong\u003e — far less than what MWA requires. Less heat was generated, so fewer surrounding tissues were injured, but the tumor shrank less completely.\u003c\/p\u003e\n\n\u003cp\u003eIndividual LA studies reported the following results:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e64 patients\u003c\/strong\u003e, mean follow-up 25.7 months: VRR \u003cstrong\u003e100.00%\u003c\/strong\u003e, complete absorption \u003cstrong\u003e96.9%\u003c\/strong\u003e, recurrence \u003cstrong\u003e1.56% (1 patient)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e36 patients\u003c\/strong\u003e, mean follow-up 49.2 months: VRR \u003cstrong\u003e98.38%\u003c\/strong\u003e, complete absorption \u003cstrong\u003e100.0%\u003c\/strong\u003e, complications \u003cstrong\u003e2.80% (1 patient)\u003c\/strong\u003e, recurrence \u003cstrong\u003e5.60% (2 patients)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e34 patients\u003c\/strong\u003e, mean follow-up 22.8 months: VRR \u003cstrong\u003e96.80%\u003c\/strong\u003e, complete absorption \u003cstrong\u003e79.4%\u003c\/strong\u003e, complications \u003cstrong\u003e2.90% (1 patient)\u003c\/strong\u003e, no recurrences.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e37 patients\u003c\/strong\u003e, mean follow-up 16.5 months: complete absorption \u003cstrong\u003e32.4%\u003c\/strong\u003e, complications \u003cstrong\u003e2.70% (1 patient)\u003c\/strong\u003e, recurrence \u003cstrong\u003e2.70% (1 patient)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e30 patients\u003c\/strong\u003e, mean follow-up 13.2 months: complete absorption \u003cstrong\u003e96.7%\u003c\/strong\u003e, complications \u003cstrong\u003e3.30% (1 patient)\u003c\/strong\u003e, no recurrences.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe review authors flag two important weaknesses in the LA evidence base. First, there is not enough clinical evidence to guarantee complete tumor destruction. Second, very few studies compare LA head-to-head against MWA, RFA, surgery, or active surveillance. Most LA studies were retrospective, with short follow-up periods ranging from roughly \u003cstrong\u003e18 to 52 months\u003c\/strong\u003e. Even so, the authors conclude that LA remains a promising alternative for low-risk PTMC patients who cannot undergo surgery or who decline it for personal reasons.\u003c\/p\u003e\n\n\u003ch2 id=\"rfa\"\u003eRadiofrequency Ablation (RFA)\u003c\/h2\u003e\n\n\u003cp\u003eRadiofrequency ablation was first developed to treat \u003cstrong\u003esupraventricular tachycardias\u003c\/strong\u003e (abnormally fast heart rhythms). Its ability to deliver high temperatures and release energy instantly made it useful for solid tumors too. These solid tumors include tumors in the liver, kidney, and bone. These solid tumors also include soft-tissue tumors of the breast, head, and neck.\u003c\/p\u003e\n\n\u003cp\u003eUnder strict patient selection criteria, two retrospective studies from South Korea and one prospective study from China produced consistent, encouraging results. RFA was safe and effective as a treatment option for PTMC.\u003c\/p\u003e\n\n\u003cp\u003eResearchers led by Zhang have been evaluating RFA for PTMC and PTC for years. They retrospectively analyzed clinicopathological data from over \u003cstrong\u003e500 PTMC patients\u003c\/strong\u003e at a single center between January 2013 and December 2017 who chose RFA treatment. Complication and recurrence rates in this group were generally acceptable, each ranging from \u003cstrong\u003e0% to 4.5%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eLarger RFA studies reported the following:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e414 patients\u003c\/strong\u003e, mean follow-up 42.2 months: VRR \u003cstrong\u003e98.81%\u003c\/strong\u003e, complete absorption \u003cstrong\u003e88.4%\u003c\/strong\u003e, complications \u003cstrong\u003e3.86% (16 patients)\u003c\/strong\u003e, recurrence \u003cstrong\u003e3.62% (15 patients)\u003c\/strong\u003e. In this study, 15 patients developed local tumor progression after RFA: \u003cstrong\u003e4 patients (0.97%)\u003c\/strong\u003e developed lymph node metastasis (LNM — cancer spread to lymph nodes) and \u003cstrong\u003e10 patients (2.42%)\u003c\/strong\u003e developed recurrent PTMC.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e198 patients\u003c\/strong\u003e, mean follow-up 25.9 months: VRR \u003cstrong\u003e99.80%\u003c\/strong\u003e, complete absorption \u003cstrong\u003e45.6%\u003c\/strong\u003e, complications \u003cstrong\u003e4.50% (9 patients)\u003c\/strong\u003e, recurrence \u003cstrong\u003e0.51% (1 patient)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e133 patients\u003c\/strong\u003e: VRR \u003cstrong\u003e100.00%\u003c\/strong\u003e, complete absorption \u003cstrong\u003e91.4%\u003c\/strong\u003e, complications \u003cstrong\u003e3.00% (4 patients)\u003c\/strong\u003e, no recurrences.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e92 patients\u003c\/strong\u003e, mean follow-up 7.8 months: VRR \u003cstrong\u003e96.00%\u003c\/strong\u003e, complete absorption \u003cstrong\u003e10.2%\u003c\/strong\u003e, complications \u003cstrong\u003e4.30% (4 patients)\u003c\/strong\u003e, no recurrences.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e37 patients\u003c\/strong\u003e, mean follow-up 6.0 months: VRR \u003cstrong\u003e99.34%\u003c\/strong\u003e, complete absorption \u003cstrong\u003e97.4%\u003c\/strong\u003e, no complications, no recurrences.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e6 patients\u003c\/strong\u003e (PTMC and PTC), mean follow-up 48.5 months: VRR \u003cstrong\u003e98.50%\u003c\/strong\u003e, complete absorption \u003cstrong\u003e66.7%\u003c\/strong\u003e, no complications, no recurrences.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e94 patients\u003c\/strong\u003e, mean follow-up 64.2 months: no complications recorded, recurrence \u003cstrong\u003e1.06% (1 patient)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOne especially reassuring result came from a follow-up study at the same institution as the 414-patient trial. Ninety-four patients were successfully tracked for at least \u003cstrong\u003e5 years\u003c\/strong\u003e — the longest follow-up period identified in the review. Among them, only one developed a new lesion, and there were no other complications or lymph node metastases.\u003c\/p\u003e\n\n\u003cp\u003eNot all results were equally encouraging. Researchers led by Xiao examined RFA in \u003cstrong\u003e66 patients with PTC staged T1bN0M0\u003c\/strong\u003e (slightly larger tumors, 10–20 mm). The mean VRR reached \u003cstrong\u003e99.11%\u003c\/strong\u003e at 30 months, but \u003cstrong\u003e2 patients (3%)\u003c\/strong\u003e had malignant cells found at the edge of the ablation site, and \u003cstrong\u003e1 patient (1.5%)\u003c\/strong\u003e developed lymph node metastasis during follow-up.\u003c\/p\u003e\n\n\u003cp\u003eBecause of these findings, the review authors urge caution. They specifically warn against routine clinical use of RFA for early-stage \u003cstrong\u003eT1aN0M0\u003c\/strong\u003e PTC (tumors 10 mm or smaller) because of the risk of \u003cstrong\u003eoccult metastases\u003c\/strong\u003e — hidden cancer deposits that imaging cannot detect. Still, they conclude that RFA may be a promising option for patients who cannot tolerate surgery or who choose to decline it.\u003c\/p\u003e\n\n\u003ch2 id=\"vs-surgery\"\u003eHow Thermal Ablation Compares With Surgery\u003c\/h2\u003e\n\n\u003cp\u003eSurgery remains the first-line treatment for papillary thyroid carcinoma and serves as the benchmark against which all new techniques are judged. Several studies have compared the two approaches directly.\u003c\/p\u003e\n\n\u003cp\u003eIn benign thyroid tumors, thermal ablation already showed itself to be a strong alternative — with faster recovery, fewer complications, higher postoperative quality of life, and shorter hospital stays than thyroidectomy. The question was whether the same held true for cancer.\u003c\/p\u003e\n\n\u003cp\u003eIn one retrospective study of \u003cstrong\u003e92 PTMC patients\u003c\/strong\u003e treated with either MWA or surgery, \u003cstrong\u003eno patient in either group\u003c\/strong\u003e experienced recurrence or lymph node metastasis over a \u003cstrong\u003e42-month follow-up\u003c\/strong\u003e. The cost difference was striking: the average MWA cost was \u003cstrong\u003e9,996.5 ± 586.47 RMB (Chinese yuan)\u003c\/strong\u003e versus \u003cstrong\u003e15,342.36 ± 2,226.39 RMB\u003c\/strong\u003e for surgery (p\u0026lt;0.001 — a difference highly unlikely to be due to chance).\u003c\/p\u003e\n\n\u003cp\u003eSurgery carries its own risks. Removing the thyroid increases the chance of injuring the \u003cstrong\u003erecurrent laryngeal nerves\u003c\/strong\u003e (nerves that control the voice box) or the \u003cstrong\u003eparathyroid glands\u003c\/strong\u003e (four small glands that regulate calcium). Damage to these structures can cause hoarseness and \u003cstrong\u003ehypocalcemia\u003c\/strong\u003e (abnormally low blood calcium), which produces symptoms such as tingling, muscle cramps, and fatigue.\u003c\/p\u003e\n\n\u003cp\u003eWhen researchers expanded the comparison to \u003cstrong\u003e311 patients\u003c\/strong\u003e, the results held up:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eRecurrence rate and 5-year disease-free survival showed \u003cstrong\u003eno statistically significant difference\u003c\/strong\u003e between MWA and surgery: \u003cstrong\u003e4.2% vs 4.2%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eComplication rates were much lower with MWA: \u003cstrong\u003e4.2% vs 11.9%\u003c\/strong\u003e (p\u0026lt;0.001).\u003c\/li\u003e\n  \u003cli\u003eOperative time, blood loss, length of hospital stay, and hospital cost were all significantly reduced with thermal ablation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe table of comparative studies tells the story in numbers:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMWA vs surgery (92 patients):\u003c\/strong\u003e procedure time \u003cstrong\u003e10.19 vs 75.80 minutes\u003c\/strong\u003e; hospital stay \u003cstrong\u003e1.30 vs 7.47 days\u003c\/strong\u003e; blood loss \u003cstrong\u003e1.54 vs 33.10 mL\u003c\/strong\u003e; complications \u003cstrong\u003e4.30% (2 patients) vs 43.50% (20 patients)\u003c\/strong\u003e; recurrence \u003cstrong\u003e0 vs 0\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMWA vs surgery (prospective):\u003c\/strong\u003e procedure time \u003cstrong\u003e25.02 vs 78.80 minutes\u003c\/strong\u003e; hospital stay \u003cstrong\u003e1.77 vs 4.18 days\u003c\/strong\u003e; blood loss \u003cstrong\u003e10.32 vs 33.12 mL\u003c\/strong\u003e; complications \u003cstrong\u003e4.90% (2 patients) vs 15.20% (7 patients)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMWA vs surgery (311 patients):\u003c\/strong\u003e complications \u003cstrong\u003e4.20% (7 patients) vs 11.90% (17 patients)\u003c\/strong\u003e; recurrence \u003cstrong\u003e4.2% (7 patients) vs 4.2% (6 patients)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRFA vs surgery:\u003c\/strong\u003e procedure time \u003cstrong\u003e7.99 vs 62.90 minutes\u003c\/strong\u003e; cost \u003cstrong\u003e1,832.00 vs 2,355.00 US dollars\u003c\/strong\u003e; hospital stay \u003cstrong\u003e0.00 vs 9.35 days\u003c\/strong\u003e; blood loss \u003cstrong\u003e26.10 vs 31.60 mL\u003c\/strong\u003e; complications \u003cstrong\u003e0 vs 3.75% (3 patients)\u003c\/strong\u003e; recurrence \u003cstrong\u003e1.1% (1 patient) vs 2.5% (2 patients)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLA vs surgery:\u003c\/strong\u003e procedure time \u003cstrong\u003e25.90 vs 74.20 minutes\u003c\/strong\u003e; hospital stay \u003cstrong\u003e0.15 vs 2.58 days\u003c\/strong\u003e; complications \u003cstrong\u003e2.80% (1 patient) vs 6.70% (3 patients)\u003c\/strong\u003e; recurrence \u003cstrong\u003e5.6% (3 patients) vs 6.7% (2 patients)\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMWA vs LA (head-to-head):\u003c\/strong\u003e procedure time \u003cstrong\u003e24.00 vs 26.90 minutes\u003c\/strong\u003e; hospital stay \u003cstrong\u003e0.14 vs 0.15 days\u003c\/strong\u003e; complications \u003cstrong\u003e9.10% (3 patients) vs 2.90% (1 patient)\u003c\/strong\u003e; recurrence \u003cstrong\u003e0 vs 0\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCosmetic and quality-of-life outcomes also favor ablation. Compared with the surgery group, PTMC patients who underwent RFA scored lower on the \"problems with scarring\" and \"less interest in sex\" sections of the \u003cstrong\u003eTHYCA-QOL\u003c\/strong\u003e (a validated thyroid-cancer-specific quality-of-life questionnaire). Thermal ablation leaves almost invisible scars on the neck rather than a surgical incision.\u003c\/p\u003e\n\n\u003cp\u003eThe sexual-function finding may connect to thyroid biology. The review notes that thyroid hormone levels can influence reproductive hormone levels as well as sexual and reproductive function.\u003c\/p\u003e\n\n\u003cp\u003eDespite these advantages, the authors stress that randomized controlled studies with large patient numbers and longer follow-up are still required before these conclusions can be considered final.\u003c\/p\u003e\n\n\u003ch2 id=\"complications\"\u003eComplications and Side Effects\u003c\/h2\u003e\n\n\u003cp\u003eComplications after thermal ablation are significantly fewer than after thyroid lobectomy or total thyroidectomy. Even so, a small proportion of patients develop symptoms related to thermal damage.\u003c\/p\u003e\n\n\u003cp\u003eThe most common problems reported across studies are:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTransient hoarseness\u003c\/strong\u003e — temporary voice changes\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBurning sensation\u003c\/strong\u003e in the treated area\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHemorrhage\u003c\/strong\u003e (bleeding)\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eChoking and coughing\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eLocal infection\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eSkin burning\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHypothyroidism\u003c\/strong\u003e (underactive thyroid)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHypoparathyroidism\u003c\/strong\u003e (underactive parathyroid glands, leading to low calcium)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHematoma\u003c\/strong\u003e (a collection of blood outside blood vessels)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe reassuring news: the majority of these symptoms resolve on their own within a short time.\u003c\/p\u003e\n\n\u003cp\u003eThe review identifies two reasons why thermal damage to surrounding structures can occur. First, safety depends heavily on where the tumor sits. If the lesion lies close to the trachea (windpipe), heat can spread to sensitive nearby tissue. Second, the deliberate 5 mm safety margin around the tumor — which helps ensure complete destruction and prevents recurrence at the edges — can inadvertently affect nearby nerves and blood vessels.\u003c\/p\u003e\n\n\u003cp\u003eComparing complication rates across treatments shows a clear pattern. In comparative studies, ablation consistently produced fewer complications than surgery: 4.30% vs 43.50%, 4.90% vs 15.20%, 2.80% vs 6.70%, and 4.20% vs 11.90% in the respective studies.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow This Review Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis is a narrative review, not a new clinical trial. The authors searched the \u003cstrong\u003ePubMed database\u003c\/strong\u003e — a major index of biomedical research — for the most relevant published literature. Their search used keywords including:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\"thermal ablation\"\u003c\/li\u003e\n  \u003cli\u003e\"papillary thyroid microcarcinoma\"\u003c\/li\u003e\n  \u003cli\u003e\"microwave ablation\"\u003c\/li\u003e\n  \u003cli\u003e\"radiofrequency ablation\"\u003c\/li\u003e\n  \u003cli\u003e\"laser ablation\"\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThey comprehensively reviewed the articles found and analyzed the follow-up outcomes of the patients described in them. They also quantitatively compared specific assessment indicators after ablation — such as volume reduction rate, complete absorption rate, complication rate, and recurrence rate — to provide a more direct comparison across techniques.\u003c\/p\u003e\n\n\u003cp\u003eFollow-up in the reviewed studies ranged from \u003cstrong\u003e6 to 64.2 months\u003c\/strong\u003e. Recurrence was defined as lymph node metastasis or a new malignant lesion. Complications were defined as hoarseness, choking, coughing, local infection, skin burning, hypothyroidism, hypoparathyroidism, hemorrhage, and hematoma.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Evidence\u003c\/h2\u003e\n\n\u003cp\u003eThe authors are direct about the weaknesses in the current evidence base. Several limitations stand out.\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStudy design.\u003c\/strong\u003e The majority of clinical trials evaluating thermal ablation were retrospective (looking backward at existing records), lacked a control group, and lacked randomization. Only a few comparative studies have directly compared thermal ablation with surgery for PTMC.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePopulation bias.\u003c\/strong\u003e Most observational patients came from Asia, especially China. Results may not apply equally to other ethnic groups or regions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMissing high-level evidence.\u003c\/strong\u003e There is a lack of large, population-based, multi-ethnic randomized controlled trials to definitively evaluate efficacy and safety.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eShort follow-up for some techniques.\u003c\/strong\u003e Although the longest follow-up reached 101 months (about 8.4 years), laser ablation evidence comes mostly from studies with short follow-up, roughly 18 to 52 months.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRisk of hidden disease.\u003c\/strong\u003e Occult metastases — microscopic cancer spread not visible on imaging — remain a concern, particularly for RFA in T1aN0M0 disease.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eActive surveillance itself carries a psychological burden for some patients, which complicates comparisons. Because some patients are unwilling to live with an untreated tumor, comparing ablation outcomes against patients who chose surveillance is difficult.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eIf you have been diagnosed with papillary thyroid microcarcinoma, here is what this review suggests you should know and discuss with your care team.\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about all your options.\u003c\/strong\u003e Three broad paths exist: surgery (lobectomy with or without lymph node dissection), active surveillance, and thermal ablation. Each has different trade-offs in recovery time, scarring, cost, and risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand what the numbers mean.\u003c\/strong\u003e Volume reduction rates of 96% to nearly 100% sound dramatic, and they are. But shrinkage is not the same as complete disappearance. Complete absorption rates varied widely across studies — from about 10% to 100%, depending on the technique and how long patients were followed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRecurrence risk appears comparable to surgery in the studies reviewed.\u003c\/strong\u003e In the largest comparison, recurrence was 4.2% with microwave ablation versus 4.2% with surgery. That is 1 in 24 patients in each group. But these comparisons came from observational studies, not randomized trials.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpect fewer complications and a faster recovery with ablation.\u003c\/strong\u003e Hospital stays were measured in fractions of a day to about 2 days with ablation versus roughly 2.6 to 9.4 days with surgery. Blood loss and operating time were also much lower.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChoose an experienced center.\u003c\/strong\u003e Safety depends on tumor location and on the operator's skill. Because thermal ablation typically treats a 5 mm margin beyond the tumor, the procedure's safety profile depends heavily on where the tumor sits relative to the trachea, nerves, and blood vessels.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlan for long-term follow-up.\u003c\/strong\u003e Recurrence and new lesions can appear years later. In the reviewed studies, follow-up ranged from 6 months to 64.2 months — and some recurrences appeared late.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBe cautious with larger tumors.\u003c\/strong\u003e In patients with T1bN0M0 disease (tumors 10–20 mm), 3% had malignant cells at the ablation edge and 1.5% developed lymph node metastasis. For these patients, surgery may remain the safer choice.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe review's bottom line: thermal ablation offers the same satisfactory therapeutic effects as surgery but with minimal postoperative trauma, which can significantly improve quality of life. However, the authors emphasize that larger-sample, multicenter, prospective randomized controlled trials are urgently needed to confirm how well thermal ablation truly works for PTMC.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is thermal ablation for thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eThermal ablation uses extreme heat to destroy thyroid tumor cells without surgery. Three techniques are used for papillary thyroid microcarcinoma: microwave ablation, laser ablation, and radiofrequency ablation. All are guided by ultrasound so doctors can direct heat precisely at the tumor. The dead tissue is gradually reabsorbed by the body. It is an option for low-risk tumors 10 mm or smaller.\u003c\/p\u003e\n\u003ch3\u003eAm I a candidate for thermal ablation instead of surgery?\u003c\/h3\u003e\n\u003cp\u003eThermal ablation has been studied mainly in low-risk papillary thyroid microcarcinoma, meaning a tumor 10 mm or smaller confined to the thyroid with no lymph node or distant spread. It may suit patients who cannot undergo surgery or who decline it. For tumors 10–20 mm, one study found malignant cells at the ablation edge in 3% of patients, so surgery may remain safer.\u003c\/p\u003e\n\u003ch3\u003eHow does thermal ablation compare with surgery for recovery and complications?\u003c\/h3\u003e\n\u003cp\u003eIn the reviewed studies, thermal ablation produced far fewer complications than surgery, with rates like 4.2% versus 11.9% in a 311-patient comparison. Hospital stays were shorter, operating times and blood loss were lower, and costs were reduced. Recurrence rates were similar: 4.2% with microwave ablation versus 4.2% with surgery in that same comparison. These were observational studies, not randomized trials.\u003c\/p\u003e\n\u003ch3\u003eWhat does a 99% volume reduction rate mean?\u003c\/h3\u003e\n\u003cp\u003eVolume reduction rate is the percentage by which tumor volume shrank after treatment. Rates of 96% to nearly 100% were reported across studies. But shrinkage is not the same as complete disappearance. Complete absorption rates varied widely, from about 10% to 100%, depending on the technique and how long patients were followed. Ask your care team what these numbers mean for your specific tumor.\u003c\/p\u003e\n\u003ch3\u003eWhat side effects can happen after thermal ablation?\u003c\/h3\u003e\n\u003cp\u003eReported complications include transient hoarseness, burning sensation, hemorrhage, choking, coughing, local infection, skin burning, hypothyroidism, hypoparathyroidism, and hematoma. Most resolve on their own within a short time. Safety depends on tumor location, because heat can spread to nearby structures like the trachea, and the deliberate 5 mm safety margin can affect nearby nerves and blood vessels.\u003c\/p\u003e\n\u003ch3\u003eWill the cancer come back after thermal ablation?\u003c\/h3\u003e\n\u003cp\u003eIn the reviewed studies, recurrence after thermal ablation appeared comparable to surgery. In the largest comparison, recurrence was 4.2% with microwave ablation versus 4.2% with surgery, or 1 in 24 patients in each group. However, these were observational studies, not randomized trials. Recurrence and new lesions can appear years later, so long-term follow-up is important.\u003c\/p\u003e\n\u003ch3\u003eWhy do doctors still recommend surgery for some small thyroid cancers?\u003c\/h3\u003e\n\u003cp\u003eSurgery remains the first-line treatment for papillary thyroid carcinoma and the benchmark against which new techniques are judged. It carries risks such as injury to nerves controlling the voice box or parathyroid glands, causing hoarseness or low calcium. For larger tumors (10–20 mm), one study found malignant cells at the ablation edge in 3% of patients and lymph node metastasis in 1.5%, so surgery may be safer.\u003c\/p\u003e\n\u003ch3\u003eI was just diagnosed with papillary thyroid microcarcinoma — when should I get a second opinion before choosing surgery or thermal ablation?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is worth considering when the choice between surgery, active surveillance, and thermal ablation is unclear. Recurrence was 4.2% with microwave ablation versus 4.2% with surgery in the largest comparison, but those results came from observational studies, not randomized trials. Ablation also depends heavily on tumor location and operator skill, and for tumors 10–20 mm, 3% had malignant cells at the ablation edge. An independent review of your ultrasound, pathology, and tumor location can clarify which path fits. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Methods description Thermal Ablation for Papillary Thyroid Microcarcinoma- How Far We Have Come\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e \u003cem\u003eCancer Management and Research\u003c\/em\u003e, 2020; volume 12, pages 13369–13379. Published by Dove Press. DOI: 10.2147\/CMAR.S287473.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticle type:\u003c\/strong\u003e Review article.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research. It summarizes and translates a published scientific review. Individual treatment decisions should always be made in consultation with a qualified medical team who can evaluate your specific tumor characteristics, location, and overall health.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47458062631068,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0599\/5449\/5644\/files\/ddn-medical-article-thermal-ablation-for-papillary-thyroid-microcarcinoma-what-patients-should-know-about-this-promising-treatment-hero.png?v=1790202381","url":"https:\/\/diagnosticdetectives.com\/fi\/products\/thermal-ablation-for-papillary-thyroid-microcarcinoma-what-patients-should-know-about-this-promising-treatment","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}